Product Detailed Description

Liposomal Puerarin 70% — High Purity Kudzu Isoflavone Supplement

Product Overview

Liposomal Puerarin 70% is a premium-grade dietary supplement ingredient delivering puerarin in an advanced liposomal delivery system. Puerarin, also known as Kakonein, is an isoflavone C-glucoside (8-β-D-glucopyranosyl-4′,7-dihydroxyisoflavone) and the most abundant flavonoid derivative in the root of Pueraria lobata (Willd.) Ohwi. It is the primary bioactive compound responsible for the traditional medicinal properties of kudzu root, including cardiovascular protection, alcohol metabolism support, and metabolic regulation.

Puerarin has been extensively studied for its diverse pharmacological activities, including antioxidant, anti-inflammatory, cardioprotective, neuroprotective, and anticancer effects. It acts as a 5-HT2C receptor antagonist and has been investigated for applications in cardiovascular disease, diabetes, osteoporosis, and alcohol-related conditions. However, its clinical potential is limited by poor oral bioavailability. Liposomal encapsulation addresses this challenge by protecting puerarin from degradation and enhancing its delivery to target cells.

Why Liposomal Technology?

Conventional puerarin exhibits low systemic bioavailability due to its poor water solubility, low intestinal permeability, and rapid metabolism following oral administration. These limitations significantly hinder its absorption and therapeutic efficacy.

Liposomal encapsulation provides three critical advantages:

1. Digestive Protection — The phospholipid bilayer shields puerarin from enzymatic degradation and premature metabolism during digestive transit, preserving its intact molecular structure until reaching target cells.

2. Enhanced Cellular Uptake — liposomes fuse directly with intestinal cell membranes, facilitating efficient cellular delivery and bypassing passive diffusion limitations. In a pharmacokinetic study comparing puerarin proliposomes to conventional tablets, the liposomal formulation demonstrated a relative bioavailability of 145.6%, with a significantly higher peak plasma concentration (Cmax 1.12 ± 0.21 mg/L vs 0.98 ± 0.17 mg/L) and reduced clearance (CL 10.1 ± 2.2 L/h vs 16.5 ± 4.6 L/h). A separate study in rats reported a relative bioavailability of 168% for liposomal puerarin suspension compared to puerarin solution.

3. Sustained Release — Liposomal formulations provide controlled release of puerarin, with prolonged circulation time and sustained plasma concentrations. A study on puerarin-loaded liposomes (T/R-L@PUE) achieved an encapsulation efficiency of 70.56% and a drug loading efficiency of 9.20%, with an average particle size of 127.20 nm.

Product Specifications

Key Features

• High Purity — Standardized to ≥70% puerarin by HPLC, ensuring consistent active content.

• Liposomal Enhancement — Phospholipid bilayer encapsulation achieves a relative bioavailability of 145.6–168% compared to conventional puerarin formulations, with encapsulation efficiency up to 70.56% and nanoscale particle size of approximately 127 nm.

• Antioxidant and Anti-Inflammatory — Puerarin acts as an intracellular ROS scavenger, an autophagy inducer, and a ferroptosis inhibitor, protecting cells from oxidative damage.

• Cardiovascular Support — Puerarin increases cerebral and coronary blood flow, reduces vascular resistance, and supports cardiovascular function.

• Metabolic Regulation — Puerarin demonstrates hypoglycemic activity and supports lipid metabolism, with clinical trials evaluating its effects in metabolic-associated fatty liver disease (MAFLD).

• Neuroprotective Effects — Puerarin protects hippocampal neurons from β-amyloid-induced neurotoxicity, demonstrating potential for cognitive support.

• Water-Dispersible — Suitable for capsules, tablets, powder drink mixes, and functional beverages.

• Batch Traceability — Complete COA, HPLC chromatogram, and identity data provided for each batch.

Application & Formulation Guidance

Recommended Dosage

Clinical studies have evaluated puerarin oral supplementation at 90.2 mg per day and 180 mg per day in randomized controlled trials. A 12-week crossover trial in healthy Chinese men used puerarin granules at 90.2 mg daily. An ongoing randomized controlled trial in patients with metabolic-associated fatty liver disease (MAFLD) uses puerarin at 180 mg per day for 12 weeks. For general antioxidant and cardiovascular support, 90–180 mg daily is commonly used. Liposomal formulations may allow for more efficient utilization of lower doses due to enhanced bioavailability.

Shipping & Lead Time

• Stock Orders: 3–5 business days after payment confirmation.

• Bulk / Custom Orders: 2–3 weeks, depending on quantity and customization requirements.

• Shipping Methods: International Express (FedEx, DHL, UPS), air freight, and sea freight.

• Coverage: Worldwide shipping, including remote areas.